Bringing model-based prediction to oncology clinical practice: A review of Pharmacometrics principles and applications

Oncologist

Volumn 21, Issue 2, 2015, Pages 220-232

  Buil Bruna, Núria ^a,b   López Picazo, José María ^b,c   Martín Algarra, Salvador ^b,c   Trocóniz, Iñaki F ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Biological and disease models; Computer simulations; Individualized medicine; Patient specific modeling

Indexed keywords

ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; DIFLOMOTECAN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; LENALIDOMIDE; MOTESANIB; SUNITINIB; VASCULOTROPIN 165; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL PRACTICE; DISEASE COURSE; DRUG BINDING; DRUG DISPOSITION; DRUG RESPONSE; MATHEMATICAL PARAMETERS; OVERALL SURVIVAL; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL PROCESSING; TUMOR GROWTH; TUMOR VOLUME; ADVERSE DRUG REACTION; COMPUTER SIMULATION; HUMAN; NEOPLASMS; ONCOLOGY; PATHOLOGY; PHARMACOKINETICS; TRENDS;

ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PHARMACOKINETICS;

EID: 84957536145     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0322     Document Type: Review

References (92)

1. Ette EI, Williams PJ. Pharmacometrics: The Science of Quantitative Pharmacology. New York, NY: Wiley-Interscience, 2007.
2. Milligan PA, Brown MJ, Marchant B et al. Modelbased drug development: A rational approach to efficiently accelerate drug development. Clin Pharmacol Ther 2013;93:502–514.
3. Department of Health and Human Services. Challenge and Opportunity on the Critical Path to New Products. Rockville, MD: US Food and Drug Administration, 2004.
4. Bonate PL. What happened to themodeling and simulation revolution? Clin Pharmacol Ther 2014; 96:416–417.
5. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: Routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980;8:553–571.
6. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981;9:635–651.
7. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: Routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983;11:303–319.
8. Rowland M, Peck C, Tucker G. Physiologicallybased pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011;51:45–73.
9. Tsukamoto Y, Kato Y, Ura M et al. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: The mechanism for tumor-selective accumulation of 5-FU. Pharm Res 2001;18:1190–1202.
10. Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science:Aworkshop report (Georgetown University,Washington, DC,May 29-30, 2002). AAPS PharmSci 2004;6:E6.
11. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982;16:143–166.
12. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994;56:248–252.
13. Glassman PM, Balthasar JP. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med 2014;11:20–33.
14. Mager DE, JuskoWJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28:507–532.
15. Dirks NL, Nolting A, Kovar A et al. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head andneck. J Clin Pharmacol 2008;48:267–278.
16. Panoilia E, Schindler E, Samantas E et al. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemother Pharmacol 2015;75:791–803.
17. Bennett TA, Montesinos P, Moscardo F et al. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: A bridge to individualized medicine. Clin Lymphoma Myeloma Leuk 2014;14:305–318.
18. Derendorf H, Lesko LJ, Chaikin P et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 2000;40:1399–1418.
19. Atkinson AJ, Colburn WA, DeGruttola VG et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95.
20. Altman DG, Riley RD. Primer: An evidencebased approach to prognostic markers. Nat Clin Pract Oncol 2005;2:466–472.
21. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors inmultiple regression: A bad idea. Stat Med 2006;25:127–141.
22. Taylor JM, Ankerst DP, Andridge RR.Validation of biomarker-based risk prediction models. Clin Cancer Res 2008;14:5977–5983.
23. Almufti R, Wilbaux M, Oza A et al. A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann Oncol 2014;25:41–56.
24. Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 1998; 45:229–239.
25. Wilbaux M, Hénin E, Oza A et al. Dynamic modeling in ovarian cancer: An original approach linking early changes inmodeled longitudinal CA- 125 kinetics and survival to help decisions in early drug development. Gynecol Oncol 2014; 133:460–466.
26. Buil-Bruna N, López-Picazo JM, Moreno-Jiménez M et al. A population pharmacodynamic model for lactate dehydrogenase and neuronspecific enolase to predict tumor progression in small cell lung cancer patients. AAPS J 2014;16:609–619.
27. Buil-Bruna N, Sahota T, López-Picazo JM et al. Early prediction of disease progression in small cell lung cancer: Toward model-based personalized medicine in oncology. Cancer Res 2015;75: 2416–2425.
28. Wilbaux M, Tod M, De Bono J et al. A joint model for the kinetics of CTC count and PSA concentration during treatment in metastatic castration-resistant prostate cancer. CPT Pharmacometrics Syst Pharmacol 2015;4:277–285.
29. Keizer RJ, Schellens JHM, Beijnen JH et al. Pharmacodynamic biomarkers in model-based drug development in oncology. Curr Clin Pharmacol 2011;6:30–40.
30. You B, Harvey R, Henin E et al. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. Br J Cancer 2013; 108:1810–1816.
31. Kogan Y, Halevi-Tobias K, Elishmereni M et al. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. Cancer Res 2012;72:2218–2227.
32. Kronik N, Kogan Y, ElishmereniMet al. Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. PLoS One 2010; 5:e15482.
33. Hansson EK, Ma G, Amantea MA et al. PKPD modeling of predictors for adverse effects and overall survival in sunitinib-treated patients with GIST. CPT Pharmacometrics Syst Pharmacol 2013;2:e85.
34. Hansson EK, Amantea MA, Westwood P et al. PKPD modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as predictors of tumor dynamics and overall survival following sunitinib treatment in GIST. CPT Pharmacometrics Syst Pharmacol 2013;2:e84.
35. FDA—Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics—May 2007. Available at http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf.
36. Bender BC, Schindler E, Friberg LE. Population pharmacokinetic-pharmacodynamic modelling in oncology: A tool for predicting clinical response. Br J Clin Pharmacol 2015;79:56–71.
37. Ribba B, Holford NH, Magni P et al. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacometrics Syst Pharmacol 2014; 3:e113.
38. Claret L, Girard P, Hoff PM et al. Model-based prediction of phase III overall survival in colorectal canceronthe basis of phase II tumor dynamics. JClin Oncol 2009;27:4103–4108.
39. Innovative Medicines Initiative. Strategic Research Agenda, 2008/2011. Available at http://www. imi.europa.eu/content/research-agenda. Accessed September 12, 2015.
40. Harnisch L, Matthews I, Chard J et al. Drug and disease model resources: A consortium to create standards and tools to enhance model-based drug development. CPT Pharmacometrics Syst Pharmacol 2013;2:e34.
41. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.
42. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol 2004; 22:4442–4445.
43. Sharma MR, Maitland ML, Ratain MJ. RECIST: No longer the sharpest tool in the oncology clinical trials toolbox—Point. Cancer Res 2012;72: 5145–5149; discussion 5150.
44. Robert C, Ribas A, Wolchok JD et al. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109–1117.
45. van Baren N, Bonnet MC, Dréno B et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005;23:9008–9021.
46. Kruit WH, van Ojik HH, Brichard VG et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005;117:596–604.
47. Di Giacomo AM, Danielli R, Guidoboni M et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009;58:1297–1306.
48. Little RF, Pluda JM, Wyvill KM et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 2006;107:4650–4657.
49. Motzer RJ, Rini BI, McDermott DF et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 2015;33:1430–1437.
50. Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003;30:83–103.
51. Friberg LE, Henningsson A, Maas H et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002;20:4713–4721.
52. Hansson EK, Friberg LE. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia. Cancer Chemother Pharmacol 2012;69: 881–890.
53. van Kesteren C, Zandvliet AS, Karlsson MO et al. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 2005;23:225–234.
54. Latz JE, Rusthoven JJ, Karlsson MO et al. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 2006;57:427–435.
55. Gupta P, Friberg LE, Karlsson MO et al. A semimechanisticmodel of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J Clin Pharmacol 2010;50:679–687.
56. Joerger M, Huitema AD, Richel DJ et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European Organization for Research and Treatment of Cancer- Pharmacology and Molecular Mechanisms Group and New Drug Development Group. Clin Cancer Res 2007;13:6410–6418.
57. Quartino AL, Friberg LE, Karlsson MO. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs 2012;30:833–845.
58. Fetterly GJ, Grasela TH, Sherman JW et al. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin Cancer Res 2008;14:5856–5863.
59. Sandström M, Lindman H, Nygren P et al. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 2005;23:413–421.
60. Soto E, Staab A, Tillmann C et al. Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemother Pharmacol 2010;66:785–795.
61. Léger F, Loos WJ, Bugat R et al. Mechanismbased models for topotecan-induced neutropenia. Clin Pharmacol Ther 2004;76:567–578.
62. Soto E, Keizer RJ, Troćoniz IF et al. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: Two case studies. Invest New Drugs 2011; 29:984–995.
63. Mangas-Sanjuan V, Buil-Bruna N, Garrido MJ et al. Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules. J Pharmacol Exp Ther 2015;354:55–64.
64. Agoram B, Heatherington AC, Gastonguay MR. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy.AAPS J 2006;8:E552–E563.
65. Fetterly GJ, Owen JS, Stuyckens K et al. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. Cancer Chemother Pharmacol 2008;62:135–147.
66. Houk BE, Bello CL, Poland B et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: Results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66:357–371.
67. Keizer RJ, Gupta A, Mac Gillavry MR et al. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E 7080. J Pharmacokinet Pharmacodyn 2010;37: 347–363.
68. Xie R, Mathijssen RH, Sparreboom A et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 2002;72:265–275.
69. Troćoniz IF, Cendros JM, Soto E et al. Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a phase I dose finding study in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012; 70:239–250.
70. Hénin E, You B, VanCutsem E et al. A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. Clin Pharmacol Ther 2009; 85:418–425.
71. Holford N. A time to event tutorial for pharmacometricians. CPT Pharmacometrics Syst Pharmacol 2013;2:e43.
72. Collett D. Modelling Survival Data in Medical Research. Boca Raton, FL: CRC Press, 2003.
73. Wang Y, Sung C, Dartois C et al. Elucidation of relationship between tumor sizeand survival in nonsmall- cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009;86:167–174.
74. Ribba B, Holford N, Mentré F. The use of model based tumor-size metrics to predict survival. Clin Pharmacol Ther 2014;96:133–135.
75. Buil-Bruna N, Dehez M, Manon A et al. Population PK/PD modelling of the biomarker and progressionfreesurvival effects of lanreotideautogel in patients with non-functioning gastroenteropancreatic neuroendocrine tumors. PAGE 2015;24: 3628a. Available at http://www. Page-Meeting.Org/?abstract53628.AccessedNovember24,2015.
76. Desmée S, Mentré F, Veyrat-Follet C et al. Nonlinear mixed-effect models for prostate-specific antigen kinetics and link with survival in the context of metastatic prostate cancer: a comparison by simulation of two-stage and joint approaches. AAPS J 2015;17:691–699.
77. Zandvliet AS, Schellens JH, Beijnen JH et al. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. Clin Pharmacokinet 2008;47:487–513.
78. Jacqmin P, Snoeck E, van Schaick EA et al. Modelling response time profiles in the absence of drug concentrations: Definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 2007;34:57–85.
79. Bauer R. NONMEM Users Guide Introduction to NONMEM 7.2.0. Ellicott City, MD: ICON Development Solutions, 2011.
80. Lavielle M. MONOLIX (MOdeles NOn LIn éaires à effets miXtes). Orsay, France: MONOLIX Group, 2005.
81. Veyrat-Follet C, Bruno R, Olivares R et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000;68:677–687.
82. Claret L, Lu JF, Sun YN et al. Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. Cancer Chemother Pharmacol 2010;66:1141–1149.
83. Bruno R, Jonsson F, ZakiMet al. Simulation of clinical outcome for pomalidomide plus low-dose dexamethasone in patients with refractory multiple myeloma based on week 8 M-protein response. Blood 2011;118:1881a.
84. Kanefendt F, Lindauer A, Kinzig M et al. Modeling sunitinib and biomarker response as potentialpredictors of time to progression in patients with metastatic colorectal cancer. PAGE 2012;21: 2354a. Available at http://www.Page-Meeting.Org/? Abstract 52354. Accessed November 25, 2015.
85. E. Schindler P, Westwood M, Amantea EK et al. PKPD-modeling of standard uptake value (SUV) in gastro-intestinal stromal tumors (GIST) patients treated with sunitinib. PAGE 2012;21: 2595a. Available at http://www.Page-Meeting. Org/?Abstract 52595. Accessed November 25, 2015.
86. Claret L, Lu JF, Bruno R et al. Simulations usinga drug-diseasemodeling framework and phase II data predict phase III survival outcome in first-line nonsmall-cell lung cancer. Clin Pharmacol Ther 2012;92: 631–634.
87. Bruno R, Lindbom L, Schaedeli Stark F et al. Simulations to assess phase II noninferiority trials of different doses of capecitabine in combination with docetaxel for metastatic breast cancer. CPT Pharmacometrics Syst Pharmacol 2012;1: e19.
88. Quartino A, Claret L, Li J et al. Evaluation of tumor size metrics to predict survival in advanced gastric cancer. PAGE 2013;22:2812a. Available at http://www.Page-Meeting.Org/?Abstract 52812. Accessed November 25, 2015.
89. Claret L, Gupta M, Han K et al. Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastaticcolorectalcancer. JClinOncol2013;31:2110–2114.
90. Claret L, Gupta M, Han K et al. Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab. J Clin Pharmacol 2014;54:253–257.
91. Suleiman AA, Frechen S, Scheffler M et al. Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib. J Thorac Oncol 2015;10:84–92.
92. Jusko WJ, Ko HC, Ebling WF. Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Biopharm 1995;23:5–8; discussion 9–10.